Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CII and USIBC form healthcare partnership

This article was originally published in Scrip

Executive Summary

The Confederation of Indian Industry (CII) has lent its support to the US-India Business Council (USIBC)-led Coalition for Healthy India.

You may also be interested in...

Dr Reddy’s Signals Reset In Europe Business

Strong showing by Dr Reddy’s in Europe in fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. China growth strategy 'still valid', management maintains.

India Pharma Webinar: COVID-19 Impact, Dealing With Business Continuity

Informa Markets’ recent webinar on COVID-19 and its impact on the Indian pharmaceutical industry deliberated a range of burning issues across the sector’s spectrum of activities, including efforts to stem India’s vulnerable dependency on active pharmaceutical ingredients imported from China, current trends for the excipients and pharma machinery segments and how industry is handling demand-supply disruptions in these challenging times.

Cipla Propels 'Lung Leadership' Plans

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts